Member Info for BasilAlderman

Yes, if the Ebola cases continue to rise globally then NCYT's kit, which is designed to have a broad detection profile, will be back in demand. For those that don't know the NCYT primers detected over 95% of the last Ebola virus. i.e. they have the proven kit that Government's will want. So, if the current outbreak sadly continues to gain traction and the WHO communicate further concerns there will be an opportunity for NCYT to win contracts. One to watch.

Huge news in the RNS today from THAT about catapulting Thalia to a clinical-stage RNA therapeutics company. Deal is expected to be fundamentally value accretive. THAT under its new ceo is a turn around stock without a doubt now. Huge news today. Buy and hold.

IMM's patent protections for P140 extend up to 2045. FACT!

Yes, I agree, which major global helium player isn't going to want to do a JV with such high recordings of helium of over 9% at the Itumbula West-1 well? Industry off takers will be all over the HE1 data now. The first we will know about commercial terms will be when a JV for HE1's Tanzania project is confirmed. That will be a huge day for HE1 investors.

The summary reads very well also by the way: "Our findings validate P140 peptide treatment as a safe and specific strategy to halt GB progression and establish the clinical relevance of extracellular MAPT/tau as a biomarker for therapeutic success in GB *Glioblastoma (GB) is the most aggressive brain cancer, with poor prognosis due to infiltrative invasion of glioma stem cells (GSCs) and the immunosuppressive tumor microenvironment (TME). Looks like IMM are finally getting traction with P140. One to watch closely!

Yes, the article also states "We found that administration of P140 peptide in an immunocompetent GB mouse model with both patient-derived GSCs and GB cell lines, neutralizes GB-induced PC CMA upregulation resulting in ablation of PC-tumor cell interactions and triggering of a secretome toxic to tumor cells". This is looking more interesting every day. PubMed is not just any old publication either. It's a US Govt website of the National Library of Medicine. i.e. it's credible and is widely acknowledged as an influencer publication read by R&D departments at major pharma. Maybe the promised P140 deal in 2026 is not that far away after all ???

Yes, parties can ask a court to postpone a hearing to allow them time to negotiate an out-of-court settlement. It happens all the time. This is certainly a possibility.

Yes, the interim order was previously granted in MPL's favour by the NCLAT on 10 December (2025). This is the same court overseeing the case today. Why would they change their mind having already ruled in MPL's favour on 10th December, that's the question? Having ruled in MPL's favour a few months ago will they do the same this time? We will shortly found out.

Yes, we might have a few hours to wait for official yes or no news. The Update on the Ongoing Legal Proceedings on 18th December was issued at 15.29pm and the 10th April Update on Committee of Creditors' Meeting was at 16.23pm.

In answer to your question Carey Olsen are Legal Advisers. Whether they have acted for MPL in this case or not who knows. Hope this helps.

Yes, there's massive upside with massive risk but it is worth noting that the interim order was previously granted in MPL's favour by the NCLAT on 10 December (2025). This is the same court overseeing the case today. Why would they change their mind having already ruled in MPL's favour on 10th December, that's the question? Who knows but it is certainly going to be an interesting 24-48 hours here. Having ruled in MPL's favour a few months ago will they do the same this time?

Summary of the GOV UK link below RE Project STRONG, clearly stating its ALRT:

Supplier

Defence Holdings PLC

Contract value

£226,617 excluding VAT

£271,940.40 including VAT

Below the relevant threshold

Earliest date the contract will be signed

15 June 2026

Contract dates (estimated)

15 June 2026 to 14 September 2026

3 months

Main procurement category

Services

The nature of these data sources are highly sensitive and unable to be shared more broadly. Project STRONG is the prototyping of an integrated capability that fuses intelligence into a single analytical platform, generates Courses of Action, and supports rapid, human-controlled deployment of authorised effects across cyber, information and supply-chain domains.

The Authority is seeking to place the contract with the Supplier under Schedule 5 of the Procurement Act 2023, on the MODs terms & Conditions.

Yes, apparently the delayed Defence Investment Plan (DIP) is expected to be published next week, ahead of the NATO defence ministers' summit later in the month. Right Place / Right Time for ALRT.

Breaking news, 36 mins ago: NHS warns staff to 'prepare for Ebola outbreak in the UK' as eye-bleeding disease kills hundreds in Africa: 'Stock up on PPE and isolate patients ASAP'

Courtesy of Daily Mail https://www.dailymail.com/health/article-15873619/NHS-staff-prepare-Ebola-outbreak-UK-Africa.html?ito=social-facebook-uknews

NHS staff have been told to prepare for potential Ebola cases reaching the UK amid a fast-growing outbreak of the deadly virus in Africa.

In updated guidance, the UK Health Security Agency (UKHSA) has urged hospitals, GPs and frontline services to ensure they are ready to rapidly identify and isolate suspected patients, warning that while the risk to Britain remains low, imported cases are possible.

Healthcare providers have been instructed to check they have adequate supplies of personal protective equipment (PPE) and ensure staff are trained in its use, alongside clear protocols for managing suspected cases.

Clinicians are being reminded to consider Ebola in any patient who is acutely unwell with a fever and has travelled from affected regions within the past 21 days, reflecting the virus’s incubation period.

Under the guidance, suspected cases must be treated urgently, with patients isolated immediately in a single room and assessed by staff using appropriate protective measures.

Strict infection control procedures are required, and cases must be escalated rapidly to specialist public health teams, as Ebola is a notifiable disease in the UK.

The warning comes as an outbreak of the rare Bundibugyo strain of Ebola continues to spread in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, after being declared a Public Health Emergency of International Concern by the World Health Organisation in May.

The latest figures suggest there have been hundreds of suspected cases and dozens of confirmed deaths, with numbers continuing to rise as testing and surveillance improve.

Yes you don't have to be a rocket scientist to work out that with spot prices for helium going for as much as $3,500 per thousand cubic feet (Mcf) the potential for GEX is huge.

Yes and GEX investors are in the right sector at exactly the right time. The current helium market is $7 Billion USD and rising fast.

Yes and as we know Helium is used in computer and smartphone components, MRI systems, medical treatments, superconducting magnets, fibre optic cables, microscopes, particle accelerators and space rocket launches, so demand is only going continue to grow. It's also worth pointing out that Helium is priced at up to 50 times the price of LNG in liquid form and is one of THE most expensive industrial gases. The current annual global demand for helium is 6.6 Bcf and spot contract prices can range between $650 and $3,500 per thousand cubic feet (Mcf). The current market is $7 Billion USD and rising. So, as you quite rightly point out "what's not to like!". GEX investors are in the right sector right time etc.

Yes, Gheko, it's all about getting your entry price right. I bought in to HE1 at 0.26 and sold a big chunk at at 2.4p. A x 9. I still have a free float on HE1 now from that purchase price. I bought in to GEX at 3.1p and fully expect 25p at least this year. This is a risk reward share with huge upside if you are buying at these prices. We all know GEX has already hit 10p this year.

Yes, people writing off the possibility of another serious NCYT share gain would be wise to remember the last Ebola and Covid gains. Many of us did very nicely indeed on the back of those gains during what was an awful situation for those impacted by the diseases. If the Ebola cases continue to rise globally then NCYT's kit, which is designed to have a broad detection profile, will be back in demand. For those that don't know the NCYT primers detected over 95% of the last Ebola virus. i.e. they have the proven kit that Government's will want. So, if the current outbreak sadly continues to gain traction and the WHO communicate further concerns there will be an opportunity for NCYT to win contracts. One to watch.

Yes, if Nicholas Tulloch, Michael Whitlow, Ian Bagnall, and Martin Gouldstone announce plans to appoint a proven executive director from the pharmaceutical industry then they would have my vote. I can't see them running the PYC business without such a person. One to watch over the coming days and weeks.